Hyperglycemic complications associated with adjuvant chemotherapy of breast cancer. A cancer and leukemia group B (CALGB) study

Many adjuvant chemotherapy regimens used for breast cancer include prednisone, which has the potential to cause hyperglycemia. We reviewed the results of three CALGB studies employing prednisone as part of adjuvant therapy to determine the incidence and severity of hyperglycemic complications. All t...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of clinical oncology Vol. 9; no. 6; p. 533
Main Authors Ellis, M E, Weiss, R B, Korzun, A H, Rice, M A, Norton, L, Perloff, M, Lesnick, G J, Wood, W C
Format Journal Article
LanguageEnglish
Published United States 01.12.1986
Subjects
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Breast Neoplasms - drug therapy
Breast Neoplasms - surgery
Cisplatin - administration & dosage
Clinical Trials as Topic
Combined Modality Therapy
Female
Fluorouracil - administration & dosage
Humans
Hyperglycemia - chemically induced
Hyperglycemia - mortality
Methotrexate - administration & dosage
Middle Aged
Neoplasm Staging
Prednisone - administration & dosage
Vincristine - administration & dosage
Online AccessGet more information

Cover

More Information
Summary:Many adjuvant chemotherapy regimens used for breast cancer include prednisone, which has the potential to cause hyperglycemia. We reviewed the results of three CALGB studies employing prednisone as part of adjuvant therapy to determine the incidence and severity of hyperglycemic complications. All treatment regimens included cyclophosphamide, methotrexate or doxorubicin, 5-fluorouracil, and vincristine in addition to prednisone. Among 1,237 evaluable patients receiving a five-drug regimen including prednisone, there were 98 patients (7.9%) who experienced any degree of hyperglycemia. Thirty patients (2.4% overall; 30.6% of those having any hyperglycemia) had severe or life-threatening degrees of hyperglycemia, including two patients whose hyperglycemia contributed directly to death. We conclude that prednisone administration as part of adjuvant chemotherapy regimens in breast cancer produces an appreciable incidence of hyperglycemia. Serum glucose levels should be monitored during therapy to help prevent the occasional severe or life-threatening episode of hyperglycemia in these patients.
ISSN:0277-3732
DOI:10.1097/00000421-198612000-00013